FIELD: medicine.
SUBSTANCE: invention refers to medicine, particularly to psychopharmacology, and concerns an agent for treating and preventing disorders of autism spectrum, representing glycine, immobilized on detonation nano-diamond particles size of 2–10 nm, with content of glycine from 1 to 21±3 wt%.
EFFECT: claimed device allows improving effectiveness of medical treatment and prevention of autism and expand the range of effective and safe psychotropic agents.
1 cl, 5 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| AGENT IMPROVING PROCESS OF TRAINING, MEMORY AND COGNITIVE FUNCTIONS, AS WELL AS FOR SYMPTOMATIC THERAPY AT AUTISTIC DISORDERS | 2015 |
|
RU2612791C1 |
| AGENT FOR CORRECTING AUTISM SPECTRUM DISORDERS | 2017 |
|
RU2666598C1 |
| ANXIOLYTIC AND METHOD FOR PREPARING IT | 2013 |
|
RU2519755C1 |
| MEDICATION FOR TREATING AND PREVENTION OF ALCOHOLISM | 2014 |
|
RU2574001C1 |
| METHOD OF PRODUCING COPOLYMER OF SODIUM CARBOXY-METHYLCELLULOSE AND GOSSYPOL AND USE THEREOF IN COMPLEX THERAPY OF PATIENTS WITH AUTISTIC DISORDERS AND COGNITIVE IMPAIRMENTS | 2010 |
|
RU2453559C1 |
| AGENT WITH ANTI-STROKE ACTION, AND METHOD FOR PREPARING IT | 2013 |
|
RU2521404C1 |
| ANTIDEPRESSANT DRUG AND METHOD FOR PREPARING IT | 2013 |
|
RU2519759C1 |
| ANXIOLYTIC AGENT AND PHARMACEUTICAL COMPOSITION WITH ANXIOLYTIC EFFECT | 1999 |
|
RU2155065C1 |
| METHOD FOR PERIPHERAL VISION PRIORITY DETERMINING, CHARACTERISTIC FOR PEOPLE WITH AUTISM SPECTRUM DISORDER | 2019 |
|
RU2724018C1 |
| USING SELECTIVE ANTAGONIST OF GLUAMATE RECEPTOR Ro-256981 FOR TARGETED EFFECT ON COGNITIVE FUNCTIONS | 2011 |
|
RU2496495C2 |
